Xanthelasma

Back

Background

Xanthelasma are yellowish plaques that occur most commonly near the inner canthus of the eyelid, more often on the upper lid than the lower lid. Xanthelasma palpebrarum is the most common cutaneous xanthoma. See the image below.



View Image

Xanthelesma of four eyelids in patient with hyperlipidemia.

Xanthelasma can be soft, semisolid, or calcareous. Frequently, they are symmetrical, and all four lids are sometimes involved. Xanthelasma tends to progress, coalesce, and become permanent.

The term xanthelasma is derived from the Greek xanthos (yellow) and elasma (beaten metal plate).

See Can You Recognize Benign Skin Lesions From Cancerous Ones?, a Critical Images slideshow, to help identify various skin lesions.

Pathophysiology

Xanthelasma are a type of xanthoma appearing on the eyelids. Xanthomas are depositions of yellowish cholesterol-rich material that can appear anywhere in the body in various disease states. They are cutaneous manifestations of lipidosis in which lipids accumulate in foam cells within the skin. They are often associated with hyperlipidemias, of both primary and secondary types. Some occur with altered lipoprotein composition or structure, such as lowered high-density lipoprotein (HDL) levels. They frequently occur in patients with type II hyperlipidemia and in the type IV phenotype.

Epidemiology

Frequency

United States

Xanthelasma are not uncommon.

International

In India, the incidence of xanthelasma may range from 0.3%-1.5%.[1]

Mortality/Morbidity

These lesions have no premalignant potential; however, see Differentials.

A study by Christoffersen et al finds that xanthelasmata can be a predictor of risk for myocardial infarction, ischemic heart disease, severe atherosclerosis, and death in the general population, independent of well-known cardiovascular risk factors (eg, plasma cholesterol, triglyceride concentrations). On the other hand, arcus senilis of the cornea has been found not to be an important independent predictor of risk.[2]

Sex

In case studies of patients with xanthomatosis, a predominance of xanthelasma in women has been seen; women, 32%, and men, 17.4%.

Age

The age of onset ranges from 15-73 years, with a peak in the fourth and fifth decades.

Prognosis

Recurrence is common. Patients need to be aware that studies completed after surgical excision showed recurrence in up to 40% of patients. This percentage is higher with secondary excisions. Of these failures, 26% occurred within the first year and were more likely to occur in patients with hyperlipidemia syndromes and in those with all 4 eyelids affected.

Patient Education

For excellent patient education resources, see eMedicineHealth's Cholesterol Center. Also, visit eMedicineHealth's patient education articles High Cholesterol, Cholesterol Charts, Lifestyle Cholesterol Management, and Cholesterol Lowering Medications.

History

Xanthelasma are the most common type of xanthoma. They often present in the absence of xanthomas elsewhere on the body, although, histologically, they are the same.

Once plaques are established, they will remain static or increase in size.

Patients generally present with concerns of their appearance, rather than symptoms of discomfort or inflammation.

Physical

Xanthelasma or xanthoma palpebrarum usually are located on the medial side of the upper eyelids.

Lesions are yellowish and soft, and they form plaques.

Generally, these lesions do not affect the function of the eyelids, but ptosis has been known to occur.

Causes

Most individuals with xanthelasma have a lipid disorder. Many xanthelasma occur in normolipemic persons who may have low HDL cholesterol levels or other lipoprotein abnormalities.

Eruptive xanthomas can be seen in primary and secondary causes of hyperlipidemia.

Examples of primary genetic causes include familial dyslipoproteinemia, familial hypertriglyceridemia, and familial lipoprotein lipase deficiency.

Secondary causes of hyperlipidemia include those related to various diets, drugs, disorders of metabolism, and some diseases. Diets rich in saturated fats and cholesterol, alcohol excess, and weight gain can cause severe but reversible hypercholesterolemia. Drugs that may cause altered lipid profiles include glucocorticoids, estrogens, anabolic steroids, some antihypertensive medications, retinoids, cyclosporine, cimetidine, certain antiepileptic drugs, and tamoxifen. Hypothyroidism is the most common secondary cause of hyperlipidemia after dietary causes are considered.

Uncontrolled diabetes is a common cause of secondary hyperlipidemia.

Laboratory Studies

Since more than 50% of patients with xanthelasma have lipid disorders, it is recommended that their plasma lipid levels are obtained, including LDL cholesterol and HDL cholesterol levels, triglyceride level, and apolipoprotein B100 level. Xanthelasma are usually an obvious clinical diagnosis, but, in rare cases, other lesions can simulate the appearance and may be associated with disorders of a more serious nature. If there is any doubt, surgical excision and pathologic analysis should be performed.

Histologic Findings

Xanthelasma are composed of xanthoma cells. These are foamy histiocytes laden with intracellular fat deposits primarily within the upper reticular dermis. The main lipid that is stored in hyperlipidemic and normolipidemic xanthelasmas is cholesterol. Most of this cholesterol is esterified.

Medical Care

Dietary restriction and pharmacologic reduction of serum lipids, although important in the overall care of a patient with abnormal lipids, yield only limited response in the treatment of xanthelasma.

Surgical Care

Numerous options are available for the removal of xanthelasma palpebrarum, including surgical excision, argon and carbon dioxide laser ablation, chemical cauterization, electrodesiccation, and cryotherapy.

Surgical excision

For small linear lesions, excision is recommended, as scarring should blend in with the surrounding eyelid tissue. Smaller bulging lesions can be "uncapped" and removed; then, the flap can be replaced and sutured.

Doi recommends using a surgical microscope, undermining between the tumor and the orbicularis oculi with an 11 blade, raising the flap and carefully removing the tumor piece by piece with microscissors from the reverse side, and then suturing the flap with 7-0 nylon.[4]

In full-thickness excisions, the lower lid is more prone to prominent scarring, as the tissue tends to be thicker. Simple excision of larger lesions risks eyelid retraction, ectropion, or the need for more complicated reconstructive procedures. When xanthelasma removal has been incorporated into routine blepharoplasty, extending the incisional limits increases the risk for ectropion or webbing.



View Image

Case presentation of excision of recurrent xanthelasma. Recurrent xanthelasma bilateral upper lids; previous excision combined with blepharoplasty; pa....



View Image

Close-up view of recurrent xanthelasma right upper lid. Note the scar from previous excision by a plastic surgeon. Careful examination reveals subtle ....



View Image

Xanthelasma. External view, 1 week after surgery. Sliding and rotational flaps from residual lateral dermatochalasis used for medial excisional gap.



View Image

Xanthelasma. Top image, 4 weeks after surgery; lower image, before surgery.

Carbon dioxide and argon laser ablation

Enhanced hemostasis, better visualization, lack of suturing, and speed have been cited as reasons to use this technique; however, scarring and pigmentary changes can occur.

Chemical cauterization

The use of chlorinated acetic acids has been found to be effective in the removal of xanthelasma. These agents precipitate and coagulate proteins and dissolve lipids. Monochloroacetic acid, dichloroacetic acid, and trichloroacetic acid have been used with good results. Haygood used less than 0.01 mL of 100% dichloroacetic acid with excellent results and minimal scarring.[5] Intralesional heparin sodium[6] and pingyangmycin[7] have been described for xanthelasma but are not yet conventional treatments.

Electrodesiccation and cryotherapy

Electrodesiccation and cryotherapy can destroy xanthelasmas when they are superficial but may require repeated treatments. Cryotherapy may cause scarring and hypopigmentation.

Complications

Ectropion and cutaneous nasal webbing may occur after excision of xanthelasma lesions.

Hypopigmentation may occur after trichloroacetic acid application.

If xanthelasma extend deep into the orbicularis muscle, the lesions may not respond to surface ablation techniques.

Further Outpatient Care

Patients should receive follow-up care for medical and surgical treatment.

What is xanthelasma?What is the pathophysiology of xanthelasma?What is the epidemiology of xanthelasma in the US?What is the mortality and morbidity associated with xanthelasma?What is the sexual predilection of xanthelasma?Which age groups have the highest prevalence of xanthelasma?What is the prognosis of xanthelasma?Where can patient education resources for xanthelasma be found?What are the signs and symptoms of xanthelasma?Which physical findings are characteristic of xanthelasma?What causes xanthelasma?Which conditions should be included in the differential diagnoses for xanthelasma?What are the differential diagnoses for Xanthelasma?What is the role of lab tests in the workup of xanthelasma?Which histologic findings are characteristic of xanthelasma?How is xanthelasma treated medically?What is the role of surgery in the treatment of xanthelasma?What is the role of surgical excision in the treatment of xanthelasma?What is the role of carbon dioxide and argon laser ablation in the treatment of xanthelasma?What is the role of chemical cauterization in the treatment of xanthelasma?What is the role of electrodesiccation and cryotherapy in the treatment of xanthelasma?What are complications of xanthelasma?

Author

Andrew A Dahl, MD, FACS, Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Edsel Ing, MD, MPH, FRCSC, Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Active Staff, Michael Garron Hospital (Toronto East Health Network); Consulting Staff, Hospital for Sick Children and Sunnybrook Hospital, Canada

Disclosure: Nothing to disclose.

Additional Contributors

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Ron W Pelton, MD, PhD, Private Practice, Colorado Springs, Colorado

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Tracey A Schmucker, MD, to the development and writing of this article.

References

  1. Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma Palpebrarum-clinical and biochemical profile in a tertiary care hospital of Delhi. Indian J Clin Biochem. 2007 Sep. 22 (2):151-3. [View Abstract]
  2. Christoffersen M, Frikke-Schmidt R, Schnohr P, et al. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study. BMJ. 2011 Sep 15. 343:d5497. [View Abstract]
  3. Santaella RM, Ng JD, Wilson DJ. Carbon Dioxide Laser-Induced Combustion of Extravasated Intraocular Silicone Oil in the Eyelid Mimicking Xanthelasma. Ophthal Plast Reconstr Surg. 2011 Feb 22. [View Abstract]
  4. Doi H, Ogawa Y. A new operative method for treatment of xanthelasma or xanthoma palpebrarum: microsurgical inverted peeling. Plast Reconstr Surg. 1998 Sep. 102(4):1171-4. [View Abstract]
  5. Haygood LJ, Bennett JD, Brodell RT. Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg. 1998 Sep. 24(9):1027-31. [View Abstract]
  6. Ren J, Zeng LY, Chen MH. Treatment of Grade I and II types of xanthelasma palpebrarum with intralesional heparin sodium. Dermatol Ther. 2018 Nov. 31 (6):e12723. [View Abstract]
  7. Wang H, Shi Y, Guan H, Liu C, Zhang W, Zhang Y, et al. Treatment of Xanthelasma Palpebrarum With Intralesional Pingyangmycin. Dermatol Surg. 2016 Mar. 42 (3):368-76. [View Abstract]
  8. Basar E, Oguz H, Ozdemir H, et al. Treatment of xanthelasma palpebrarum with argon laser photocoagulation. Argon laser and xanthelasma palpebrarum. Int Ophthalmol. 2004 Jan. 25(1):9-11. [View Abstract]
  9. Bergman R. Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol. 1998 May. 37(5):343-5. [View Abstract]
  10. Egan CA, Patel BC, Morschbacher R, et al. Atypical lymphoid hyperplasia of the eyelids manifesting as xanthelasma-like lesions. J Am Acad Dermatol. 1997 Nov. 37(5 Pt 2):839-42. [View Abstract]
  11. Gladstone, Geoffrey, Myint, Shoib. Xanthelasma. Roy FH and Fraunfelder FT, eds. Current Ocular Therapy. 2000. Vol. 5.: 452-3.
  12. Howard GR. Xanthelasma. Roy FH, ed. Masters Technique in Ophthalmic Surgery. 1995. 520-2.
  13. Ozdol S, Sahin S, Tokgozoglu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein (a). Int J Dermatol. 2008 Aug. 47(8):785-9. [View Abstract]
  14. Usatine RP. A cutaneous manifestation of a systemic disease. West J Med. 2000 Feb. 172(2):84. [View Abstract]
  15. Ustunsoy E, Demir Z, Coskunfirat K, et al. Extensive bilateral eyelid ptosis caused by xanthoma palpebrarum. Ann Plast Surg. 1997 Feb. 38(2):177-8. [View Abstract]
  16. Ribera M, Pintó X, Argimon JM, Fiol C, Pujol R, Ferrándiz C. Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med. 1995 Nov. 99 (5):485-90. [View Abstract]
  17. Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdal-On M, et al. Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol. 1996 Mar. 76 (2):107-10. [View Abstract]
  18. Watanabe A, Yoshimura A, Wakasugi T, Tatami R, Ueda K, Ueda R, et al. Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis. 1981 Feb-Mar. 38 (3-4):283-90. [View Abstract]

Xanthelesma of four eyelids in patient with hyperlipidemia.

Case presentation of excision of recurrent xanthelasma. Recurrent xanthelasma bilateral upper lids; previous excision combined with blepharoplasty; patient insistent on repeat excision and blepharoplasty; advised of lagophthalmos risk due to medial position and lack of medial dermatochalasis.

Close-up view of recurrent xanthelasma right upper lid. Note the scar from previous excision by a plastic surgeon. Careful examination reveals subtle infiltration in the lateral aspect of scar.

Xanthelasma. External view, 1 week after surgery. Sliding and rotational flaps from residual lateral dermatochalasis used for medial excisional gap.

Xanthelasma. Top image, 4 weeks after surgery; lower image, before surgery.

Case presentation of excision of recurrent xanthelasma. Recurrent xanthelasma bilateral upper lids; previous excision combined with blepharoplasty; patient insistent on repeat excision and blepharoplasty; advised of lagophthalmos risk due to medial position and lack of medial dermatochalasis.

Close-up view of recurrent xanthelasma right upper lid. Note the scar from previous excision by a plastic surgeon. Careful examination reveals subtle infiltration in the lateral aspect of scar.

Xanthelasma. External view, 1 week after surgery. Sliding and rotational flaps from residual lateral dermatochalasis used for medial excisional gap.

Xanthelasma. Top image, 4 weeks after surgery; lower image, before surgery.

Xanthelesma of four eyelids in patient with hyperlipidemia.